إعلان
إعلان

DRMA

DRMA logo

Dermata Therapeutics, Inc. Common Stock

2.12
USD
برعاية
-0.06
-2.57%
٠٨ يناير, ١٦:٠٠ UTC -5
مغلق
exchange

بعد الإغلاق

2.15

+0.02
+0.99%

تقارير أرباح DRMA

النسبة الإيجابية المفاجئة

DRMA تفوق 13 من 18 آخر التقديرات.

72%

التقرير التالي

بيانات التقرير القادم
١٧ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$1.57
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
-4.85%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-92.38%

Dermata Therapeutics, Inc. Common Stock earnings per share and revenue

On ١٤ نوفمبر ٢٠٢٥, DRMA reported earnings of -1.65 USD per share (EPS) for Q3 25, missing the estimate of -1.62 USD, resulting in a -1.74% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.49% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 المحللين forecast an EPS of -1.57 USD, with revenue projected to reach -- USD, implying an نقصان of -4.85% EPS, and -- of --% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, Dermata Therapeutics, Inc. Common Stock reported EPS of -$1.65, missing estimates by -1.74%, and revenue of $0.00, 0% as expectations.
The stock price moved down -7.49%, changed from $3.07 before the earnings release to $2.84 the day after.
The next earning report is scheduled for ١٧ مارس ٢٠٢٦.
Based on 3 المحللين, Dermata Therapeutics, Inc. Common Stock is expected to report EPS of -$1.57 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان